Spravato (intranasal esketamine) is an FDA-approved, clinic-administered treatment that can produce rapid antidepressant effects in adults with treatment-resistant depression. It also treats depressive symptoms alongside acute suicidal ideation, when used with an oral antidepressant. The catch, and it’s a real one: every dose happens in a certified clinic under a federal REMS program, with direct supervision and at least two hours of monitoring. Nobody takes this home.
TL;DR:
- Spravato requires clinic administration with at least two hours of monitoring under a REMS program, and it cannot be used at home.
- It is approved for treatment-resistant depression after two or more antidepressant failures and for depressive symptoms with acute suicidal ideation in adults.
- Response can occur within hours to days, with long-term benefits reducing relapse risk by about 51 percent when maintained appropriately.
- Contraindications include uncontrolled hypertension, active substance use, certain psychotic disorders, pregnancy, and vascular conditions; insurance often requires prior authorization.
- Effectiveness varies among patients, with some responding after a few sessions and others needing reassessment if no benefit by four weeks.
Table of Contents
- What Spravato Is and How It Works
- Who Is a Candidate for Spravato
- Clinical Evidence: Effectiveness, Speed, and Durability
- Dosing, Administration Steps, and REMS Safety Requirements
- Side Effects, Risks, and Clinical Monitoring
- What a Treatment Session Looks Like and How to Prepare
- Long-Term Maintenance, Relapse Prevention, and Stopping Treatment
- How Spravato Compares to Ketamine Infusions and Traditional Antidepressants
- Nortex Psychiatry: How We Provide Spravato and What to Expect
- What Realistic Progress Looks Like
- How to Book an Evaluation at Nortex Psychiatry
- Sources
- FAQ
What Spravato Is and How It Works
Esketamine is the S-enantiomer of ketamine, delivered as a nasal spray rather than an infusion. We think of it less as “ketamine’s cousin” and more as ketamine’s more regulated, more studied sibling. It carries its own FDA approval, its own dosing schedule, and its own set of safety rules that don’t map cleanly onto how ketamine is used off-label elsewhere.
The mechanism is where things get interesting, and where patients usually ask the most questions. Traditional antidepressants like SSRIs work on serotonin, norepinephrine, or dopamine. That process takes weeks to reshape mood circuitry, which is part of why so many people give up before the drug ever gets a fair shot. Esketamine works differently. It blocks NMDA receptors, which triggers a burst of glutamate activity in the brain. That surge appears to drive rapid synaptic changes, essentially helping the brain rebuild some of the connections that chronic depression seems to wear down.
We don’t want to overstate the science here. Researchers still don’t have a complete picture of exactly how the glutamate cascade translates into mood improvement. What they do have is consistent clinical observation: patients often report shifts in mood within hours to days, not weeks. That’s the practical difference that matters most to someone who has already spent months or years cycling through oral medications with limited relief.
A few things separate esketamine from a standard antidepressant trial:
- It acts on a different neurotransmitter system (glutamate/NMDA) instead of the serotonin-norepinephrine-dopamine pathways most antidepressants target.
- Onset is measured in hours to days rather than weeks.
- It’s delivered intranasally in a clinical setting, not swallowed at home.
- It’s approved specifically as an add-on to oral antidepressants, not usually as a standalone therapy.
If you’ve tried two or three antidepressants and felt like you were just waiting around for something that never fully arrived, this mechanism difference is the reason Spravato gets discussed as a genuinely separate category of treatment, not just another pill on the list.
Who Is a Candidate for Spravato
Treatment-resistant depression has a specific clinical definition, and it’s worth knowing before you assume you qualify. It generally means you’ve tried at least two different antidepressants, at adequate doses, for adequate durations, without meaningful improvement. That’s the threshold most psychiatrists, and the FDA approval itself, used to define TRD.
Spravato has two approved uses. The first is as an add-on treatment for adults with TRD who haven’t responded to standard antidepressant trials. The second is for depressive symptoms in adults with major depressive disorder who are experiencing acute suicidal ideation or behavior, again used together with an oral antidepressant rather than alone. That second use matters. It means Spravato has a role in genuinely urgent situations, not just chronic, slow-moving depression.
Not everyone is a fit, though. In our work, some of the hardest conversations happen when a patient is excited about esketamine but has a medical history that makes it inappropriate. Exclusions typically include:
- Uncontrolled or poorly managed hypertension, since esketamine can raise blood pressure transiently.
- Active substance use disorder, particularly with a history of ketamine or PCP misuse.
- Certain psychotic disorders, where dissociative effects could worsen underlying symptoms.
- Pregnancy or breastfeeding, given limited safety data.
- Age restrictions. Spravato is approved for adults; it is not approved for adolescents or children.
- Aneurysmal vascular disease or history of intracerebral hemorrhage, due to the blood pressure effect.
Access is its own layer of complexity, separate from clinical eligibility. Spravato can only be administered in a healthcare setting certified through the SPRAVATO REMS Program, which means your prescriber, and the clinic itself, has to be enrolled before you can start. Insurance coverage varies quite a bit by plan. Many commercial and Medicare plans now cover Spravato for documented TRD, but prior authorization is common, and the paperwork often requires proof of prior antidepressant failures. It’s worth calling your insurer before you get emotionally invested in a start date.
Clinical Evidence: Effectiveness, Speed, and Durability
Here’s the honest summary: Spravato works faster than most antidepressants, and for a meaningful subset of patients, the benefit holds up over time. It doesn’t work for everyone, and the durability depends heavily on staying in some form of maintenance care.
The pivotal trials that led to FDA approval tested doses of 56 mg and 84 mg against placebo, both combined with a newly initiated oral antidepressant. One of the foundational studies found dose-related improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS), with meaningful separation from placebo showing up by day 8, and continued improvement sustained through open-label follow-up phases. That speed is the headline. Patients who had been depressed for years, sometimes decades, were seeing measurable symptom reduction within a week.
Long-term data show something almost as important as the initial response: in patients who reached stable remission or stable response, continuing Spravato with an oral antidepressant cut relapse risk by 51 percent compared with switching to antidepressant plus placebo. That same SUSTAIN research program found remission rates holding around 46 percent in long-term extension cohorts, with some patients followed for an average exposure of close to 43 months.
That’s a genuinely strong signal for a psychiatric intervention. Most depression treatments show gradual, modest effects. This one shows fast onset and a durability curve that looks more like a chronic disease management model, closer to how we think about long-term blood pressure or diabetes control, than a short antidepressant course.
We’d be doing you a disservice if we didn’t mention the caveats, though. A few things temper the enthusiasm:
- Response is heterogeneous. Some patients respond dramatically within days; others need several sessions before noticing anything, and a portion don’t respond meaningfully at all.
- The pivotal trial populations were carefully screened, meaning real-world patients with more complex comorbidities may see different results.
- There’s a real clinical decision point after the initial four-week induction phase. If you’re not seeing benefit by then, continuing at the same dose usually isn’t the right call, and your psychiatrist should be reassessing rather than defaulting to “give it more time.”
- Long-term data is strong but still comes from a smaller, more selected population than the general TRD population walking into a clinic.
None of this changes the core takeaway. For a condition that has historically been managed with slow, trial-and-error medication changes, having an option with day-one-to-day-eight response data and multi-year relapse prevention data is a meaningfully different conversation than what psychiatry could offer a decade ago.
Dosing, Administration Steps, and REMS Safety Requirements
Spravato dosing follows a fairly rigid structure, and that rigidity is by design, not bureaucratic overkill. The induction phase typically runs four weeks, with sessions twice weekly. Standard doses include measured amounts delivered by a specific number of devices. Each device is used with a five-minute gap before the next spray, and patients typically self-administer under direct staff supervision, meaning you handle the device yourself, but a trained clinician is watching the entire process.
Here’s what a typical dosing day actually looks like, step by step:
- Check-in and baseline vitals. Blood pressure and pulse are recorded before any medication is given.
- Self-administration under supervision. You use the nasal device yourself, following the timed spacing between sprays, while staff observes.
- Post-dose monitoring begins immediately. This is where prescribing information requires at least two hours of observation, including pulse oximetry and repeat blood pressure checks.
- Discharge assessment. A clinician confirms your blood pressure has returned to an acceptable range and that dissociative or sedative effects have resolved enough for safe departure.
- Documented handoff. You’re not permitted to drive yourself home. The clinic records the dose and monitoring outcomes as part of REMS reporting requirements.
That two-hour minimum isn’t arbitrary. It’s built into the REMS Program Overview as a non-negotiable safety floor, and clinics that skip it risk their certification. The REMS structure also requires that clinics enroll patients formally, train staff on monitoring protocols, and document each dosing session, generally within seven days of administration.
Home use isn’t permitted, full stop, and that shapes how you’ll need to plan your life around treatment. Twice-weekly sessions for a month means eight clinic visits before your provider even reassesses whether induction is working. We tell patients honestly: this is a logistics commitment, not just a medical one. Plan for the appointment window itself, plus roughly two hours of monitoring, plus a ride home. If your schedule can’t absorb that for a month, it’s worth discussing timing with your psychiatrist before you start rather than after your third missed session.
Side Effects, Risks, and Clinical Monitoring
Dissociation is the side effect almost everyone asks about, and reasonably so. Depending on how it’s measured across phase 3 trials, somewhere between 61 percent and 84 percent of patients reported some dissociative symptoms on standardized scales, things like feeling detached from your surroundings or a sense of unreality. It’s usually mild to moderate and resolves within the observation window. Sedation, measured by a standardized alertness scale, showed up in roughly 48 percent to 61 percent of patients.
Other common effects include dizziness, nausea, and a transient rise in blood pressure. That blood pressure increase is exactly why vitals get checked before dosing, during the observation period, and before discharge. Most patients tolerate this without issue, but it’s part of why uncontrolled hypertension is a contraindication rather than a soft caution.
The more serious, less common risks deserve honest treatment too. Respiratory depression has occurred at higher-than-recommended doses, and there’s a documented potential for temporary loss of consciousness during the dissociative window. Esketamine is also classified as a Schedule III controlled substance, reflecting a real, if generally low in supervised medical settings, potential for misuse. This is part of why the REMS structure exists in the first place: it’s not just about tracking side effects, it’s about preventing diversion and ensuring every dose happens where someone can respond if things go sideways.
Clinics manage this through a few concrete steps:
- Blood pressure thresholds that trigger extended monitoring or a delayed discharge if readings don’t normalize.
- Continuous pulse oximetry throughout the observation period.
- Rescue protocols on hand for significant blood pressure elevation or prolonged dissociation.
- A clear decision point to hold or adjust a dose if a prior session produced concerning symptoms.
Pro Tip: Arrange your ride home before your first appointment, not the morning of. Same-day driving isn’t permitted, and scrambling for a ride while mildly dissociated is a genuinely bad way to end an otherwise successful session.
Patient counseling covers a few practical, unglamorous but essential points: arrange an escort, don’t plan to drive yourself that day, and expect a substance-use screening as a routine part of intake, not an accusation. If you’ve had prior issues with ketamine or PCP misuse, be upfront about it. It changes the risk calculus your psychiatrist has to weigh, and hiding it doesn’t protect you, it just removes information your provider needs.
What a Treatment Session Looks Like and How to Prepare
The night before your first session, most of the prep is about timing, not anxiety management, though we understand plenty of both shows up anyway. Product labeling recommends avoiding food for roughly two hours and liquids for about 30 minutes before dosing, since nausea is common enough that an empty stomach genuinely helps. If you use nasal corticosteroids or decongestants, talk to your provider about timing. Those can interfere with esketamine absorption if used too close to your dose.
A typical first visit unfolds in a fairly predictable order:
- Arrival and vitals check. Blood pressure, pulse, and a quick symptom check-in before anything starts.
- Supervised self-administration. You use the device under direct staff observation, with the required spacing between sprays.
- Observation period. Most patients are clinically ready for discharge within 90 to 120 minutes, though a smaller number need the full monitoring window or longer.
- Discharge check. Vitals need to be stable and dissociative effects need to have resolved enough for safe transport home.
Aftercare instructions are simple but matter: rest that evening, skip alcohol, and call the clinic if you notice unusual sustained dizziness, chest discomfort, or blood pressure symptoms in the hours after you leave. Most side effects resolve well before you’re discharged, so anything that shows up hours later, rather than during the visit, is worth a call rather than a wait-and-see approach.
The induction schedule is twice weekly for the first four weeks, then your psychiatrist reassesses. If you’re responding, maintenance dosing gets individualized from there, sometimes weekly, sometimes tapering to every other week or monthly, depending entirely on how your symptoms hold between sessions.
Long-Term Maintenance, Relapse Prevention, and Stopping Treatment
The maintenance phase is where a lot of the real strategy lives, and where patients sometimes get impatient in ways that work against them. The SUSTAIN research program established that continuing Spravato with an oral antidepressant after stable remission cut relapse risk by roughly half compared with dropping to antidepressant plus placebo. That’s a strong argument against stopping the moment you feel better.
The typical strategy we use is straightforward in concept: taper the dosing frequency down to the least frequent schedule that still holds your symptoms steady, rather than stopping outright. For some patients that’s every other week. For others, monthly dosing is enough to maintain what the induction and early maintenance phases achieved. There’s no universal timeline here. It gets built around your specific response pattern and reassessed regularly, not set once and forgotten.
Stopping treatment early, before your psychiatrist has had a chance to taper you down deliberately, raises relapse risk meaningfully. TRD tends to be a chronic, recurring condition, not a problem that resolves permanently after one good month. In our work, we have learned that patients who frame Spravato as “the thing that fixed me” rather than “the thing that’s currently managing this” are the ones most likely to stop too soon and relapse within months.
A few principles guide durable, long-term success:
- Maintenance dosing gets spaced out gradually, never stopped abruptly.
- Oral antidepressants continue alongside Spravato for most patients, not instead of it.
- Psychotherapy, when added, tends to support the gains rather than compete with them.
- Follow-up appointments track mood between sessions, not just how you feel in the clinic that day.
How Spravato Compares to Ketamine Infusions and Traditional Antidepressants
The comparison patients ask about most is Spravato versus IV ketamine infusions, and the honest answer is that they’re related but not interchangeable. Spravato carries full FDA approval for TRD and for depressive symptoms with acute suicidal ideation. IV ketamine, by contrast, is generally used off-label for depression, meaning it hasn’t gone through the same indication-specific approval process, even though many clinics use it with real clinical benefit.
The logistics differ too. Spravato administration happens under REMS rules with a standardized dosing device and a mandatory two-hour observation window. IV ketamine infusions are typically administered in a medical setting with an IV line and continuous monitoring for the duration of the infusion, generally 40 minutes to an hour, with protocols that vary more by clinic since there’s no single federal REMS structure governing it.
A few practical distinctions worth weighing:
- Standardization. Spravato’s dosing is fixed and protocol-driven; ketamine infusion dosing varies more by provider and clinic.
- Evidence base. Spravato has a larger, FDA-reviewed trial dataset specifically for TRD; ketamine has real-world and smaller trial evidence, but less standardized regulatory backing.
- Onset. Both can act within hours to days; neither is meaningfully faster than the other for most patients.
- Insurance. Spravato’s FDA approval generally makes insurance coverage more consistent than for off-label ketamine infusions.
Which one makes sense depends on your history, your insurance situation, and how your psychiatrist weighs your comorbidities. Neither option replaces oral antidepressants outright. Both are typically layered on top of, not instead of, an existing medication plan.
Nortex Psychiatry: How We Provide Spravato and What to Expect
At Nortex Psychiatry, Spravato is one piece of a broader toolkit that includes TMS, ketamine infusion therapy, medication management, and telehealth psychiatry, serving patients across Allen, Frisco, McKinney, Plano, and the surrounding North Dallas area. We don’t hand every TRD patient the same recommendation. The right treatment depends on your history, what you’ve already tried, and what your body tolerates.
Our workflow starts with a full evaluation to confirm TRD criteria and screen for contraindications, followed by REMS enrollment once we’ve determined you’re a candidate. From there, we schedule your induction sessions, typically twice weekly, and build monitoring into every visit exactly as the REMS program requires.
For your first appointment, bring a list of every antidepressant you’ve tried, including doses and how long you stayed on each one. That history is what determines TRD eligibility and shapes insurance authorization. We’ll walk through coverage questions directly during intake rather than leaving you to figure out billing codes on your own.
What Realistic Progress Looks Like
Patients who come to us for Spravato have usually been through a long stretch of disappointment, another medication, another six weeks of waiting, another modest improvement that didn’t hold. We understand why hope feels rationed by the time someone gets here.
What we’ve learned, watching patients through induction and into maintenance, is that early response is a real signal but not a guarantee. Noticeable improvement in the first one to two weeks is a good sign. Flat response after four full weeks of induction is the point to reassess honestly with your psychiatrist rather than pushing forward on hope alone.
Follow-up visits matter more than people expect. Depression fluctuates, and a single good session doesn’t mean the work is done. If you meet the criteria for treatment-resistant depression, two or more antidepressant trials without adequate relief, an evaluation is a reasonable next step, not a last resort.
— Felix
How to Book an Evaluation at Nortex Psychiatry
Nortex Psychiatry offers evaluation, medication management, and Spravato therapy directly, without routing you through a separate infusion center or a referral chain that adds weeks to your timeline. If you meet TRD criteria, we handle REMS enrollment, insurance verification, and scheduling in the same clinic where you’re already being seen, so you’re not juggling three different providers for one treatment plan.
Your first visit focuses on confirming your treatment history and screening for the exclusions that matter, blood pressure control, substance use history, and any psychiatric conditions that could complicate dosing. We’ll also walk through what your insurance requires for prior authorization, since that paperwork moves faster when it’s handled by people who do it regularly. If you’re ready to find out whether you qualify, start with a psychiatric evaluation and we’ll take it from there.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- Initial intranasal esketamine TRD trial — PMC5838571
- DailyMed SPRAVATO prescribing information
- SPRAVATO REMS Program Overview
- SPRAVATO prescribing information (Janssen product monograph)
FAQ
What Disqualifies You From Spravato?
Uncontrolled hypertension, active substance use disorder, certain psychotic disorders, pregnancy, and a history of aneurysmal vascular disease or intracerebral hemorrhage are the main exclusions your psychiatrist screens for during evaluation.
What Is the Success Rate of Spravato?
Trial data shows rapid, dose-related improvement on standard depression scales within about a week, and long-term follow-up found remission rates around 46 percent in extension cohorts, with continued treatment cutting relapse risk by 51 percent compared with stopping.
Is It Hard to Get Prescribed Spravato?
It requires meeting treatment-resistant depression criteria, typically two or more failed antidepressant trials, plus enrollment through a REMS-certified clinic, so it takes more steps than a standard prescription but isn’t out of reach for eligible patients.
What Is the Best Medication for Treating Treatment-Resistant Depression?
There’s no single best option for every patient. Spravato is one of the more evidence-backed choices for TRD given its FDA approval and rapid onset, but the right treatment depends on your specific history, contraindications, and response to prior medications, which is exactly what a psychiatric evaluation is built to sort out.
